| 72K |
| $279K |
| 0.0% |
| 3.769% |
| 0.03% |
| 4 | CITADEL ADVISORS LLC | 57K | $219K | +462.9% | 2.961% | 0.00% |
| 5 | T3 Companies, LLC | 38K | $146K | 0.0% | 1.978% | 0.16% |
| 6 | Board of Trustees of The Leland Stanford Junior University | 36K | $139K | 0.0% | 1.872% | 0.03% |
| 7 | PFIZER INC | 31K | $134K | 0.0% | 1.629% | 0.08% |
| 8 | Lynx1 Capital Management LP | 31K | $119K | 0.0% | 1.603% | 0.01% |
| 9 | NANO CAP NEW MILLENNIUM GROWTH FUND L P | 28K | $106K | 0.0% | 1.431% | 0.08% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 19K | $74K | -33.6% | 0.995% | 0.00% |
| 11 | Shay Capital LLC | 15K | $59K | +3.6% | 0.803% | 0.00% |
| 12 | BlackRock, Inc. | 10K | $37K | 0.0% | 0.505% | 0.00% |
| 13 | VANGUARD CAPITAL MANAGEMENT LLC | 7K | $27K | 0.0% | 0.367% | 0.00% |
| 14 | Nan Fung Group Holdings Ltd | 5K | $19K | -82.9% | 0.260% | 0.01% |
| 15 | MORGAN STANLEY | 3K | $12K | -1.4% | 0.164% | 0.00% |
| 16 | VANGUARD FIDUCIARY TRUST CO | 3K | $12K | 0.0% | 0.161% | 0.00% |
| 17 | NewEdge Advisors, LLC | 3K | $10K | — | 0.132% | 0.00% |
| 18 | Tower Research Capital LLC (TRC) | 2K | $7K | +56.5% | 0.089% | 0.00% |
| 19 | UBS Group AG | 255 | $982 | -67.6% | 0.013% | 0.00% |
| 20 | SBI Securities Co., Ltd. | 130 | $501 | +1200.0% | 0.007% | 0.00% |
| 21 | JPMORGAN CHASE & CO | 42 | $165 | 0.0% | 0.002% | 0.00% |
| 22 | CITIGROUP INC | 41 | $158 | — | 0.002% | 0.00% |
| 23 | BARCLAYS PLC | 6 | $23 | 0.0% | 0.000% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in BOLT — a direct measure of their conviction.
| 47.88% |
| 0.99 pp |
| $7M |
| 27% |
| Q4 2024 | 39 | +18% | 48.87% | 0.35 pp | $10M | 18% |
| Q3 2024 | 33 | — | 49.22% | — | $12M | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
2 institutions opened new positions in BOLT during Q2 2026, while 3 fully exited. 4 added to existing positions and 17 trimmed.
BOLT institutional ownership fell by 0.95 percentage points quarter-over-quarter, with a net change of -1 holders.
The top 10 institutions account for 92.0% of all reported 13F value in BOLT, and the top 25 account for 100.0%.
Across the largest Immunology Biotech peers, institutional ownership levels are: LKFT (49.6%), YARW (1.2%), RKTO (7.9%). See the peer comparison table on this page for net buyer activity by company.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.